Evidence map›Paper›PMID 35599245›Full record

ArticleRespirology (Carlton, Vic.)2022

Targeting the human β

Nok Him Fung, Hao Wang, Ross Vlahos, Nick Wilson, Angel F Lopez, Catherine M Owczarek, Steven Bozinovski

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology (Carlton, Vic.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. SignallingERJ open research · 2025
    Article
  3. Targeting the human βRespirology (Carlton, Vic.) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nok Him FungSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria.
Hao WangSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria.
Ross VlahosSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria.ORCID 0000-0001-8443-7071
Nick WilsonCSL Limited, Parkville, Victoria, Australia.
Angel F LopezCentre for Cancer Biology, SA Pathology and UniSA, Adelaide, South Australia, Australia.
Catherine M OwczarekCSL Limited, Parkville, Victoria, Australia.
Steven BozinovskiSchool of Health & Biomedical Sciences, RMIT University, Bundoora, Victoria.ORCID 0000-0001-6533-8641
CSL (Australia) · AUSouth Australia Pathology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveChronic obstructive pulmonary disease (COPD) is a devastating disease commonly caused by cigarette smoke (CS) exposure that drives tissue injury by persistently recruiting myeloid cells into the lungs. A significant portion of COPD patients also present with overlapping asthma pathology including eosinophilic inflammation. The β

methodsWe have used our unique human β

resultshβ

conclusionThis study identifies CSL311 as a therapeutic antibody that potently inhibits immunopathology and lung injury caused by acute CS exposure.

Indexed as

Cigarette SmokingLung InjuryPulmonary Disease, Chronic ObstructiveAnimalsBronchoalveolar Lavage FluidEosinophilsHumansLungMiceMice, Inbred C57BLacute cigarette smoke exposurechronic obstructive pulmonary diseaseeosinophilsinflammationpre-clinical modelβc cytokine

Identifiers

PMID35599245
PMCPMC9542426
OpenAlexW4281292973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.